Trials / Unknown
UnknownNCT05991180
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer and Assessment of Biomarkers
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Conditions
Timeline
- Start date
- 2023-12-25
- Primary completion
- 2024-12-01
- Completion
- 2025-12-31
- First posted
- 2023-08-14
- Last updated
- 2023-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05991180. Inclusion in this directory is not an endorsement.